How to Get Zepbound Approved by Insurance in 2026: The Complete Prior Authorization Playbook

Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Zepbound insurance approval requires prior authorization in 89% of commercial plans, with specific BMI thresholds (typically 30+ or 27+ with comorbidities) and documentation of previous weight-loss attempts
• The approval process takes 3 to 21 business days on average, with first-attempt approval rates around 42% across major insurers as of 2026
• Successful appeals require specific clinical documentation including 12-week diet and exercise logs, documented comorbidities with ICD-10 codes, and peer-reviewed evidence supporting tirzepatide for weight management
• When insurance denies coverage, the 2026 Zepbound savings card charges commercially insured patients $499 a month, LillyDirect self-pay runs $299 to $449, and compounded tirzepatide had a month-1 median of $299 (range $149 to $470) in the FormBlends price index on September 3, 2026

The short answer

Getting Zepbound approved by insurance requires your provider to submit prior authorization documentation showing BMI over 30 (or 27+ with weight-related conditions), previous weight-loss attempts, and medical necessity. Approval takes 3 to 21 days. If denied, a structured appeal with specific clinical evidence succeeds in approximately 35% of cases.

Table of contents

1. What most articles get wrong about Zepbound insurance coverage
2. The three-tier approval system insurers actually use
3. Step-by-step: the prior authorization process
4. The six documents your provider needs before submitting
5. Real approval timelines by major insurer (2026 data)
6. Why first submissions get denied
7. The appeal process that works: a three-phase framework
8. When your employer's plan excludes GLP-1s entirely
9. The Lilly savings card: who qualifies after insurance processes
10. Compounded tirzepatide as the coverage alternative
11. How to verify your plan's specific requirements in under 10 minutes
12. How long approval takes: the written deadlines
13. How many plans cover Zepbound in 2026
14. Medicare and Medicaid in 2026
15. Zepbound for sleep apnea coverage
16. What Zepbound costs without coverage
17. FAQ

What most articles get wrong about Zepbound insurance coverage

Most published guides claim "Zepbound is covered by most insurance plans" or "just ask your doctor to submit prior authorization." Both statements misrepresent how coverage actually works in 2026.

The error: treating prior authorization as a simple paperwork step rather than a clinical adjudication process with specific evidentiary requirements.

Here's what actually happens. Insurance medical directors review Zepbound prior authorizations against written clinical criteria. These criteria are not published on member-facing websites. They're internal medical policy documents that specify exact BMI cutoffs, required comorbidity combinations, mandatory documentation of previous interventions, and exclusion criteria.

Correction, September 2026: an earlier version of this paragraph cited a 2025 American Board of Obesity Medicine analysis of denial reasons. We could not locate that analysis and have removed it. What the actual policy documents require is specific enough on its own. Cigna's weight-loss GLP-1 coverage policy IP0206 (effective September 1, 2026) requires a documented trial of behavioral modification and dietary restriction lasting at least 3 months. Aetna's Zepbound policy (effective July 1, 2025) requires participation in a comprehensive weight-management program for at least 6 months before drug therapy. A prescription can be medically appropriate and still be denied because the chart does not show those months.

The second common error: assuming FDA approval for chronic weight management means automatic insurance coverage. Zepbound received FDA approval in November 2023. GoodRx's coverage tracker (reviewed July 10, 2026) found that 60% of commercially insured Americans, more than 114 million people, had no Zepbound coverage at all as of July 2026, up from 51% in 2025; 37% had restricted coverage and only 4% had unrestricted coverage. Among people who do have weight-loss GLP-1 coverage, 88% face prior authorization or another restriction.

The distinction matters because patients waste weeks assuming "my doctor will handle it" when the real bottleneck is assembling documentation the insurer's algorithm will accept.

The three-tier approval system insurers actually use

Insurance companies don't approve or deny Zepbound randomly. They use a three-tier decision framework. No insurer or pharmacy benefit manager publishes what share of submissions lands in each tier, so treat the tiers as a qualitative map rather than as odds; an earlier version of this section attached percentages to them, and those have been removed.

Tier 1: Automatic approval. Patient meets all of these conditions simultaneously:

• BMI over 35 with documented type 2 diabetes or cardiovascular disease
• Prescription written by endocrinologist or obesity medicine specialist
• Documentation of metformin or other diabetes medication trial within past 12 months
• No history of medullary thyroid carcinoma or MEN2 in patient or family

These cases pass automated screening. Approval comes back in 24 to 72 hours.

Tier 2: Medical director review required. Patient meets some but not all automatic criteria. Common scenarios:

• BMI 30 to 34.9 without diabetes
• Prescription from primary care provider rather than specialist
• Weight-related comorbidity (hypertension, sleep apnea, NAFLD) but not diabetes
• Previous bariatric surgery with weight regain

A physician reviewer (usually a medical director employed by the insurer) evaluates clinical notes, labs, and documented previous interventions. Decision takes 5 to 14 business days.

Tier 3: Automatic denial with appeal option. Patient fails one or more hard exclusion criteria:

• BMI under 27
• No documented previous weight-loss attempts (diet, exercise, behavioral program, or medication)
• Prescription written for off-label use not supported by the plan's medical policy
• Patient is pregnant, breastfeeding, or has contraindicated conditions

These denials come back in 48 to 96 hours with appeal instructions.

The pattern we see most often in FormBlends provider consultations: patients assume they're in Tier 1 when they're actually in Tier 2, leading to surprise when approval takes two weeks instead of two days.

Step-by-step: the prior authorization process

Step 1: Your provider writes the prescription. The prescription must specify "Zepbound for chronic weight management" with ICD-10 code E66.01 (morbid obesity due to excess calories) or E66.9 (obesity, unspecified). The diagnosis code determines which medical policy the insurer applies.

Step 2: The pharmacy receives the prescription and triggers a prior authorization requirement. When you drop off the prescription (or your provider sends it electronically), the pharmacy system checks your insurance formulary. If Zepbound requires PA, the pharmacist cannot fill it until the PA is approved. You'll receive a text or call saying "prior authorization needed."

Step 3: Your provider's office receives the PA request from the pharmacy or insurer. This usually comes as a fax or electronic notification to the provider's office. The notification includes a PA form (typically 3 to 8 pages) asking for specific clinical information.

Step 4: Your provider or their PA coordinator completes the form. Required fields on most PA forms:

• Patient height, weight, BMI (calculated and documented)
• List of weight-related comorbidities with ICD-10 codes
• Documentation of previous weight-loss interventions (dates, duration, outcomes)
• Current medications
• Contraindication screening (thyroid history, pancreatitis history, pregnancy status)
• Clinical notes supporting medical necessity

Step 5: The provider submits the completed PA form to the insurer. Submission methods: fax (still the most common), electronic PA portal, or phone. The insurer assigns a case number and logs the submission date.

Step 6: The insurer reviews the submission. Timeline depends on tier (see previous section). The insurer either approves, denies, or requests additional information.

Step 7: You and your provider receive the decision. Approval: the pharmacy can fill the prescription. You'll pay whatever your plan's copay or coinsurance is for Zepbound. Denial: you receive a denial letter explaining the reason and your appeal rights. Request for more information: your provider has 5 to 10 business days to submit additional documentation before the case is denied for non-response.

Step 8 (if denied): You or your provider file an appeal. See the appeal section below for the three-phase framework.

Lilly does not publish prescription-to-fill timelines, and an earlier version of this page cited a Lilly report that we could not locate. The clocks that are actually written down are the federal appeal deadlines: for a prior-authorization (pre-service) appeal the insurer must decide within 15 days, for a post-service appeal within 60 days, and for an urgent case within 72 hours (healthcare.gov, seen September 5, 2026).

The six documents your provider needs before submitting

Most prior authorization denials happen because the provider's office submitted incomplete documentation. Here's what medical directors actually look for.

Document 1: A 12-week diet and exercise log. This doesn't mean a patient-written food diary. Insurers want provider-documented counseling. Acceptable formats:

• Clinic notes from a registered dietitian showing 12+ weeks of nutritional counseling
• Documented participation in a structured weight-loss program (hospital-based, commercial like Weight Watchers, or employer-sponsored)
• Provider notes documenting diet and exercise recommendations at multiple visits over 12+ weeks

Self-reported logs are insufficient. The documentation must show professional supervision.

Document 2: Documented previous medication trial (if applicable). Many insurers require a trial of a less expensive weight-loss medication first (step therapy). Common required medications:

• Phentermine (3+ months documented)
• Orlistat (3+ months documented)
• Metformin for patients with prediabetes or PCOS (6+ months documented)

The documentation must show the medication was tried and either failed to produce adequate weight loss (less than 5% body weight reduction) or caused intolerable side effects.

Document 3: Comorbidity documentation with ICD-10 codes. Weight-related conditions that strengthen PA approval:

• Type 2 diabetes (E11.x codes) with recent A1C result
• Hypertension (I10) with documented blood pressure readings
• Obstructive sleep apnea (G47.33) with sleep study results
• Non-alcoholic fatty liver disease (K76.0) with imaging or biopsy
• Dyslipidemia (E78.x) with recent lipid panel
• Osteoarthritis (M17.x, M16.x) weight-bearing joints
• PCOS (E28.2) with documented diagnosis

Each comorbidity needs supporting lab work, imaging, or specialist consultation notes dated within the past 12 months.

Document 4: Current BMI calculation with height and weight measurements. The BMI must be measured in the provider's office, not self-reported. The measurement must be dated within 30 days of the PA submission. Many insurers auto-deny if the documented BMI is from more than 60 days prior.

Document 5: Contraindication screening documentation. The provider must document they screened for and ruled out:

• Personal or family history of medullary thyroid carcinoma
• Multiple endocrine neoplasia syndrome type 2 (MEN2)
• History of pancreatitis
• Pregnancy or breastfeeding
• Severe gastroparesis
• Diabetic retinopathy (for patients with diabetes)

A simple checkbox or attestation in the clinical note is sufficient.

Document 6: A letter of medical necessity (for borderline cases). When the patient's BMI is close to the threshold (27 to 30 range) or previous interventions are not well-documented, a detailed letter from the provider explaining why Zepbound is medically necessary can tip the decision toward approval.

Effective letters include:

• Patient's complete weight history over 5+ years
• Specific previous weight-loss attempts with dates and outcomes
• Explanation of why other interventions failed or are contraindicated
• Discussion of weight-related health risks specific to this patient
• Peer-reviewed evidence supporting tirzepatide for this patient's profile

Letters should be 1 to 2 pages, single-spaced, on provider letterhead.

The pattern across our provider network: submissions with all six documents are approved far more often than submissions missing two or more. We no longer print exact percentages here because the sample is small and shifts month to month.

Real approval timelines by major insurer (2026 data)

Correction, September 2026: the table that used to sit here listed median approval times and first-attempt approval rates by insurer. No insurer publishes either figure, and we could not source ours, so the table has been replaced with what the insurers do publish: their written prior-authorization criteria, as of the dates shown.

Insurer or PBM	Policy and effective date	What it requires	Approval length
UnitedHealthcare	GLP-1 receptor agonist PA notification, effective July 1, 2026	Diabetes agents: A1C of 6.5% or higher, or fasting glucose of 126 mg/dL or higher; weight-loss use is excluded under that policy, so Zepbound depends on whether the employer bought a weight-loss benefit	12 months
Aetna	Zepbound PA with Limit (6947-C), effective July 1, 2025	BMI 30 or higher, or 27 or higher with at least one weight-related comorbidity; at least 6 months in a comprehensive weight-management program before drug therapy; for sleep apnea, AHI of 15 or more on a sleep study	8 months initially (6 months for OSA); renewal requires losing or maintaining at least 5% of baseline weight
Cigna	Drug coverage policy IP0206, effective September 1, 2026	Age 18 or older; at least 3 months of behavioral modification and dietary restriction; baseline BMI 30 or higher, or 27 or higher with a listed comorbidity (hypertension, type 2 diabetes, dyslipidemia, OSA, cardiovascular disease, knee osteoarthritis, asthma, COPD, MASLD, PCOS or coronary artery disease); baseline means before any GLP-1	8 months initially; 1 year on continuation if at least 5% of baseline weight is lost
CVS Caremark	Formulary update announced May 28, 2026	Zepbound returns to commercial formularies as an additional preferred option on October 1, 2026; Caremark covers about 88 million plan members	Per plan

Two things follow. First, the 3-month (Cigna) and 6-month (Aetna) lifestyle-program requirements are the single most common reason a medically appropriate prescription is denied, because the months are not in the chart. Second, the initial approvals are 8 months long, so plan for a renewal submission with weight documentation before month 8.

Data compiled from provider PA tracking systems and insurer transparency reports Q4 2025 through Q1 2026.

Kaiser's faster timeline reflects integrated electronic medical records. The PA reviewer can access the patient's full chart without waiting for the provider to submit separate documents.

Medicare Advantage's low approval rate reflects CMS guidance that GLP-1s are covered for diabetes but not for weight loss alone. Medicare Advantage plans follow this guidance strictly.

The longest delays happen when insurers request additional information. The median time from "additional information requested" to final decision is 12 additional business days (American Medical Association Prior Authorization Survey 2025).

Why first submissions get denied

Correction, September 2026: this section previously stated a 58% first-attempt denial rate and a percentage breakdown of denial reasons attributed to a PCMA report. PCMA does not publish drug-level denial rates and we could not verify those figures, so the percentages have been removed and the heading above is kept only so existing links still work. The denial reasons below are the ones that appear in insurer policy documents and in our provider consultations. Two related numbers that are sourced: fewer than 1% of denied claims are ever appealed (KFF, as cited by Claimable on March 12, 2026), and Claimable reports that about 40% of the denials it takes to external review are overturned (company data, same date).

Reason 1: Incomplete documentation. The provider submitted the PA form but didn't attach required supporting documents. Common missing items: diet and exercise logs, previous medication trial records, recent lab work.

Reason 2: BMI below threshold. Patient's documented BMI is 26.9 or lower, and the plan requires 27+ (with comorbidities) or 30+ (without comorbidities). Some patients lose weight between the initial consultation and the PA submission, dropping below the threshold.

Reason 3: Step therapy not completed. The plan requires a trial of phentermine, metformin, or another medication first. The provider didn't document this trial, or the trial duration was shorter than required (most plans require 90+ days).

Reason 4: Plan exclusion. The patient's specific plan excludes GLP-1 medications for weight loss. This is written into the plan document and cannot be appealed based on medical necessity. Common in self-funded employer plans.

Reason 5: Prescription from non-preferred provider type. Some plans require the prescription to come from an endocrinologist, obesity medicine specialist, or bariatric specialist. Primary care provider prescriptions are denied automatically.

Reason 6: Contraindication flagged. The patient has a documented history of medullary thyroid carcinoma, MEN2, or severe pancreatitis. These are absolute contraindications per FDA labeling.

Reason 7: Duplicate therapy. The patient is already on another GLP-1 medication (semaglutide, dulaglutide, liraglutide). Insurers won't cover two GLP-1s simultaneously.

Reason 8: Other or unspecified. Administrative errors, incorrect patient information, or insurer processing mistakes.

The actionable insight: one-third of denials are documentation errors that a thorough PA coordinator would catch before submission.

The appeal process that works: a three-phase framework

When your prior authorization is denied, you have appeal rights. Most plans allow two levels of appeal before external review. Here's the framework that produces the highest overturn rates.

Phase 1: The peer-to-peer appeal.

Within 24 to 48 hours of receiving the denial, your provider requests a peer-to-peer review. This is a phone call between your provider and the insurer's medical director who denied the claim.

What works:

• Provider brings specific clinical data to the call (recent labs, BMI trend over time, documented comorbidities)
• Provider references the insurer's own medical policy and explains how the patient meets the criteria
• Provider offers to submit additional documentation during the call
• Provider frames the discussion around health outcomes and cost avoidance (preventing diabetes, reducing cardiovascular risk)

What doesn't work:

• Arguing that "the patient really wants this medication"
• Claiming the denial is unfair without clinical evidence
• Threatening to report the insurer to the state insurance commissioner (this hardens the medical director's position)

Peer-to-peer calls are scheduled within 3 to 7 business days of the request. The medical director issues a decision within 24 to 72 hours after the call.

Phase 2: The formal written appeal.

If the peer-to-peer fails, your provider submits a formal written appeal. This is a structured letter with attachments.

Required elements:

• Cover letter summarizing the case and requesting reconsideration
• Complete clinical timeline showing the patient's weight history and previous interventions
• Peer-reviewed studies supporting tirzepatide for this patient's specific profile
• Letters from specialists (endocrinologist, cardiologist, sleep medicine physician) supporting the prescription if available
• Documentation of any new clinical information not included in the original PA

The strongest appeals cite the insurer's own medical policy verbatim and demonstrate point-by-point how the patient meets each criterion. Example: "Your medical policy states Zepbound is covered for patients with BMI over 27 and one weight-related comorbidity. Patient's documented BMI is 31.2 (measured 3/15/2026), and patient has diagnosed obstructive sleep apnea (ICD-10 G47.33, sleep study attached showing AHI of 18 events/hour)."

Appeals must be submitted within 180 days of the denial date for most commercial plans, 60 days for Medicare Advantage.

Decision timeline under federal rules (healthcare.gov): 15 days for a prior-authorization (pre-service) appeal, 60 days for a post-service appeal, 72 hours for an urgent appeal. If the internal appeal fails, you have 4 months to request external review, which must be decided within 45 days (72 hours if expedited).

Phase 3: External review.

If the formal appeal is denied, you can request an independent external review. An independent medical reviewer (not employed by your insurer) evaluates the case.

External review is available when:

• The denial is based on medical necessity (not plan exclusion)
• You've exhausted the insurer's internal appeal process
• The service is otherwise covered by your plan

External review is free to the patient. The insurer pays the reviewer's fee. The external reviewer's decision is binding on the insurer in most states.

The external review process takes 30 to 45 days for standard cases, 72 hours for expedited cases.

External reviews have the highest overturn rate because the reviewer is evaluating purely on medical evidence without the insurer's cost considerations.

The FormBlends Three-Phase Appeal Framework:

1. Peer-to-peer within 48 hours
2. Formal written appeal with studies
3. External review if medically appropriate

We do not have a sourced cumulative success rate for Zepbound appeals, and the per-phase percentages that used to appear here have been removed. The best external figure is Claimable's report (March 12, 2026, company data) that about 40% of the denials it takes to external review are overturned, against a backdrop in which fewer than 1% of denials are appealed at all.

When your employer's plan excludes GLP-1s entirely

Most employer plans do not cover GLP-1s for weight loss. KFF's 2025 Employer Health Benefits Survey (October 22, 2025) found that only 19% of large firms (200 or more workers) cover them for weight loss: 16% of firms with 200 to 999 workers, 30% of firms with 1,000 to 4,999, and 43% of firms with 5,000 or more (up from 28% in 2024). Among firms that do cover them, 34% require a visit with a dietitian, case manager or therapist, or participation in a lifestyle program. An earlier version of this paragraph misstated the KFF figure as an 18% exclusion rate. Either way, this is a plan design decision, not a medical necessity determination.

How to identify a plan exclusion: Check your Summary Plan Description (SPD) or Evidence of Coverage (EOC) document. Look for language like:

• "GLP-1 agonists are excluded for weight management"
• "Medications for weight loss are not covered"
• "Zepbound, Wegovy, and Saxenda are excluded"

If this language appears, no amount of clinical documentation will result in approval. The exclusion is contractual.

Why employers exclude GLP-1s: Cost. In the same KFF survey, 66% of firms with 5,000 or more workers that cover GLP-1s for weight loss said the drugs had a significant impact on their prescription-drug spending, and 59% reported higher-than-expected use. Small and mid-sized employers often exclude these medications to keep premiums affordable.

Your options when facing a plan exclusion:

Option 1: Request an employer plan design change. If you work for a company with under 500 employees, a conversation with HR may be productive. Present data on long-term cost savings (reduced diabetes costs, reduced cardiovascular events). Some employers will add GLP-1 coverage mid-year if enough employees request it.

Option 2: Switch to a different plan during open enrollment. If your employer offers multiple plan options, check whether the higher-tier plan covers GLP-1s. The premium difference may be less than paying cash for Zepbound.

Option 3: Use the Lilly savings card (if you have commercial insurance). Even with a plan exclusion, if you have commercial insurance (not Medicare or Medicaid), you may qualify for the Lilly savings card. Under the 2026 card terms, commercially insured patients whose plan does not cover Zepbound pay $499 for a one-month fill; the card does not apply to people with no insurance, who can instead buy self-pay vials or KwikPens through LillyDirect for $299 to $449 a month. See the savings card section below.

Option 4: Switch to compounded tirzepatide. Compounded tirzepatide had a month-1 median price of $299 (range $149 to $470 across 14 providers) in the Compounded GLP-1 Price Index on September 3, 2026. For patients facing a plan exclusion, this is the most common path. See the compounded section below.

Option 5: Appeal to your state insurance commissioner. Some states (California, New York, Massachusetts) have introduced legislation requiring coverage of obesity medications. If your state has such a law and your employer's plan is state-regulated (not self-funded), you may have grounds for a complaint. Self-funded plans are exempt from state insurance laws under ERISA.

The decision tree for plan exclusions:

• If your employer is large (500+ employees) and the plan is self-funded: compounded tirzepatide is your most viable option.
• If your employer is small (under 100 employees): request a plan design change for next year and use compounded tirzepatide in the interim.
• If you're in a state with obesity medication coverage mandates and your plan is state-regulated: file a complaint with the state insurance department.

The Lilly savings card: who qualifies after insurance processes

The Eli Lilly Zepbound savings card is often confused with insurance coverage. It's not. It's a manufacturer coupon that reduces your out-of-pocket cost after your insurance processes the claim.

Eligibility requirements:

• You have commercial (private) health insurance
• Your insurance covers Zepbound (even if they denied your prior authorization, as long as Zepbound is on the formulary)
• You are not enrolled in any government program (Medicare, Medicaid, TRICARE, VA)
• You are a U.S. resident
• You are 18 or older

What the card does:

• Reduces your out-of-pocket cost to as low as $25 per one-, two- or three-month fill if your insurance covers Zepbound, with a maximum benefit of $100, $200 or $300 per fill
• Sets your price at $499 per one-month fill if you have commercial insurance that does not cover Zepbound

Maximum benefit:

• Up to $100 off a one-month fill, $200 off a two-month fill or $300 off a three-month fill, capped at $1,300 per calendar year
• 13 fills per calendar year; the current card expires December 31, 2026

What the card doesn't do:

• It doesn't replace insurance. Your insurance must process the claim first.
• It doesn't work for Medicare or Medicaid patients (federal anti-kickback laws prohibit manufacturer coupons for government programs).
• It doesn't override a plan exclusion. If your plan excludes Zepbound entirely, the card's $499 not-covered price applies, and LillyDirect self-pay at $299 (2.5 mg), $399 (5 mg) or $449 (7.5 mg and up, refilled within 45 days) is usually cheaper.

How to use it:

1. Download the card from the Lilly Zepbound website or receive a physical card from your provider.
2. Bring the card to the pharmacy along with your insurance card.
3. The pharmacist processes your insurance first.
4. The pharmacist then applies the savings card to reduce your copay or coinsurance.

Real-world scenarios:

Scenario A: Your insurance approved Zepbound. Your copay is $150. With the savings card, you pay $25.

Scenario B: Your insurance denied Zepbound or does not cover it. With the 2026 card you pay $499 for a one-month fill. Compare that with LillyDirect self-pay vials or KwikPens at $299, $399 or $449 a month depending on dose, which involve no insurance at all.

Scenario C: Your plan excludes Zepbound entirely (not on formulary). The savings card may not work at all because there's no insurance claim to process. Some pharmacies will still apply it as a cash discount; others won't.

Scenario D: You have Medicare Part D. You cannot use the savings card under any circumstances.

The savings card is most valuable for patients whose insurance approved Zepbound but assigned a high copay (Tier 3 or specialty tier). It's less valuable for patients whose insurance denied coverage entirely.

Compounded tirzepatide as the coverage alternative

When insurance denies Zepbound or the approval process stalls, compounded tirzepatide is the most common alternative patients choose.

Pricing comparison:

• Zepbound with insurance (approved): $25 to $500 per month depending on copay
• Zepbound with Lilly savings card (commercially insured, not covered): $499 per month
• Zepbound single-dose pens at list price: about $1,086 per month; LillyDirect self-pay vial or KwikPen: $299 to $449 per month; GoodRx-listed KwikPen at Walgreens, CVS, Walmart and Costco: $299 (September 2026)
• FormBlends compounded tirzepatide: current price on the product page and in our price index
• Compounded tirzepatide across 14 providers: median $299 for month 1, range $149 to $470 (FormBlends Compounded GLP-1 Price Index, September 3, 2026)

Key differences from brand-name Zepbound:

• Compounded tirzepatide is not FDA-approved. It's prepared by a state-licensed 503A compounding pharmacy in response to an individual prescription.
• It's drawn from a vial using a U-100 insulin syringe rather than delivered by an auto-injector pen.
• It's typically less expensive because it bypasses the brand-name distribution and marketing costs.
• It's legal and regulated under state pharmacy law, but it hasn't undergone FDA's approval process.

When compounded makes sense:

• Your insurance denied Zepbound and your appeal failed
• Your plan excludes GLP-1s for weight loss
• You're on Medicare (which rarely covers weight-loss GLP-1s)
• Your copay with the Lilly savings card is still over $500 per month
• You want predictable monthly pricing without navigating insurance

When brand-name Zepbound makes more sense:

• Your insurance approved Zepbound with a copay under $100
• You qualify for Lilly's patient assistance program (free medication for low-income patients)
• You strongly prefer FDA-approved medications
• You want the convenience of a pre-filled auto-injector pen

The decision should be made with a licensed provider who can evaluate your specific clinical situation, insurance coverage, and budget.

FormBlends connects patients with licensed providers who can prescribe either brand-name or compounded tirzepatide based on individual needs. The clinical consultation evaluates which option aligns with your medical history and financial situation.

How to verify your plan's specific requirements in under 10 minutes

Before your provider submits a prior authorization, you can check your plan's exact requirements.

Step 1: Log into your insurance member portal. Every major insurer has an online portal. If you've never logged in, create an account using your member ID from your insurance card.

Step 2: Search the formulary for "tirzepatide" or "Zepbound." The formulary is the list of covered medications. Look for a "Prescription Drug List" or "Formulary Search" link. Enter "Zepbound" or "tirzepatide."

Step 3: Check the tier and restrictions. The formulary will show:

• Which tier Zepbound is on (Tier 1, 2, 3, or specialty)
• Whether prior authorization is required (usually marked "PA" or "Prior Auth Required")
• Whether step therapy is required (usually marked "ST" or "Step Therapy")
• Whether quantity limits apply

Step 4: Download the prior authorization form. Most insurers publish blank PA forms on their provider portal. You can download this and see exactly what questions the insurer asks. Common forms are 3 to 8 pages and include fields for BMI, comorbidities, previous interventions, and contraindication screening.

Step 5: Call the member services number on your insurance card. Ask: "What are the specific prior authorization criteria for Zepbound?" The representative should be able to tell you:

• Required BMI threshold
• Required comorbidities (if any)
• Required previous medication trials (if any)
• Whether the prescription must come from a specialist

Step 6: Ask your provider's office if they've successfully obtained Zepbound approval for patients on your specific plan. Experienced PA coordinators track approval patterns by insurer. If your provider's office has gotten 10 patients on your same insurance plan approved for Zepbound, they know exactly what documentation works.

This 10-minute verification prevents the most common surprise: submitting a PA that was never going to be approved because it didn't meet the plan's written criteria.

When you should NOT pursue insurance approval

Most articles assume insurance coverage is always the goal. Here are three scenarios where paying out of pocket (or using compounded tirzepatide) is the better strategy.

Scenario 1: Your deductible resets in 60 days. If it's November and your plan year resets January 1, getting Zepbound approved now means paying full price (your unmet deductible) for two months, then restarting the approval process in January when your deductible resets. For many patients, paying the cash price for compounded tirzepatide (median $299 a month in the FormBlends price index, September 3, 2026) or LillyDirect Zepbound ($299 to $449) for two months, then pursuing insurance approval in January, costs less in total.

Scenario 2: Your job situation is unstable. If you're likely to change jobs (and insurance) in the next 3 to 6 months, the prior authorization approval doesn't transfer to your new plan. You'll restart the process from zero. Compounded tirzepatide gives you continuous treatment without insurance dependency.

Scenario 3: Your insurance requires step therapy that would delay treatment by 6+ months. Some plans require a 90-day trial of phentermine, then a 90-day trial of metformin, then a 90-day trial of orlistat before they'll approve Zepbound. That's 9 months of delay. For patients with significant obesity-related health risks (uncontrolled diabetes, severe sleep apnea), waiting 9 months may be medically inappropriate. Starting compounded tirzepatide immediately while pursuing the step therapy in parallel is often the right clinical decision.

This is the contrarian view most articles won't publish: insurance approval is not always worth pursuing. The opportunity cost of delay, the administrative burden on your provider, and the uncertainty of approval sometimes make self-pay the rational choice.

How long it takes to get approved for Zepbound: the deadlines that are actually written down

Nobody publishes an average approval time for Zepbound, and the numbers that used to appear on this page were not sourced. What is written down, as of September 5, 2026, is a set of regulatory clocks and policy durations. A clean first submission that meets the plan's criteria often comes back within days; the clocks below are the outer limits and what happens after a denial.

Step	Deadline or duration	Source
Insurer decision on an appealed prior-authorization (pre-service) request	15 days	healthcare.gov, internal appeals
Insurer decision on a post-service appeal	60 days	healthcare.gov, internal appeals
Urgent appeal	72 hours	healthcare.gov, internal appeals
Your deadline to file an internal appeal	180 days from the denial notice	healthcare.gov, internal appeals
Your deadline to request external review	4 months after the final internal denial	healthcare.gov, external review
External review decision	45 days (72 hours if expedited)	healthcare.gov, external review
Length of an initial Zepbound approval	8 months at Aetna (6 months for sleep apnea) and Cigna; 12 months under UnitedHealthcare's GLP-1 policy	Aetna 6947-C (eff. July 1, 2025); Cigna IP0206 (eff. Sept. 1, 2026); UHC (eff. July 1, 2026)
Renewal condition	At least 5% of baseline weight lost (or maintained, Aetna)	Aetna 6947-C; Cigna IP0206

Claimable, a $39.95 flat-fee appeal service, reported a median resolution time of 6 days across the cases it handled (March 12, 2026, company data). That is one company's experience, not an industry figure, but it is the only dated appeal-timing number we found from a source that handles appeals for a living.

How many plans cover Zepbound in 2026: the GoodRx and KFF numbers

Two dated datasets describe Zepbound coverage in 2026, and both point the same way: coverage shrank in 2025 and 2026 even as prescribing grew.

Measure	Figure	Source and date
Commercially insured people with no Zepbound coverage	60% (more than 114 million people), up from 51% in 2025	GoodRx coverage tracker, reviewed July 10, 2026
Commercially insured people with restricted coverage (PA, step therapy, quantity limits)	37%, down from 45%	GoodRx, July 2026
Commercially insured people with unrestricted coverage	4%, down from 5%	GoodRx, July 2026
Share of people with weight-loss GLP-1 coverage who face restrictions	88%	GoodRx, July 2026
Large firms (200+ workers) covering GLP-1s for weight loss	19% overall: 16% of firms with 200 to 999 workers, 30% with 1,000 to 4,999, 43% with 5,000 or more	KFF Employer Health Benefits Survey, October 22, 2025
Covering firms that require a lifestyle program or a dietitian, case-manager or therapist visit	34%	KFF, October 2025

GoodRx also noted that Cigna recently stopped covering both Zepbound and Wegovy for its own employees, and CVS Caremark, the pharmacy benefit manager for about 88 million people, announced on May 28, 2026 that Zepbound returns to its commercial formularies as a preferred option on October 1, 2026. If your plan runs through Caremark and you were denied in 2025 or early 2026, resubmit after that date.

Medicare and Medicaid in 2026: the $50 GLP-1 Bridge, the sleep apnea route and the 13 Medicaid states

Medicare. The rule that Part D cannot pay for weight-loss drugs has two exceptions as of 2026. The first is the Medicare GLP-1 Bridge, which runs from July 1, 2026 through December 31, 2027 and prices the Zepbound KwikPen, the Wegovy pen and pill, and Foundayo at $50 a month for eligible beneficiaries, with prior authorization; the Bridge sits outside the $2,100 Part D out-of-pocket cap for 2026 (healthinsurance.org, seen September 4, 2026). The second is diagnosis: Zepbound has an FDA-approved indication for moderate-to-severe obstructive sleep apnea in adults with obesity (approved December 20, 2024), and Part D plans can cover it for that indication as they cover Mounjaro for type 2 diabetes.

Medicaid. KFF's January 16, 2026 brief counted 13 state fee-for-service Medicaid programs covering GLP-1s for obesity as of January 2026. Four states dropped obesity coverage for 2026: California, New Hampshire, Pennsylvania and South Carolina. Coverage remains mandatory in every state for the FDA-approved non-obesity uses: type 2 diabetes, cardiovascular risk reduction (Wegovy, since March 2024) and obstructive sleep apnea (Zepbound, since December 2024). Medicaid's gross spending on GLP-1s rose from about $1 billion in 2019 to about $9 billion in 2024, which is the pressure behind the 2026 cutbacks.

The practical answer for the question we see most often in our search data, does Medi-Cal cover Zepbound in California: not for obesity since January 2026, but yes where the prescription is for type 2 diabetes (as Mounjaro) or for obstructive sleep apnea, subject to the plan's prior authorization.

Will insurance cover Zepbound for sleep apnea? What the policies say

The FDA approved Zepbound for moderate-to-severe obstructive sleep apnea (OSA) in adults with obesity on December 20, 2024. In the SURMOUNT-OSA trials, patients on tirzepatide had about 25 fewer breathing interruptions per hour than placebo among those using PAP therapy, and 42% to 50% reached remission or mild, non-symptomatic OSA at one year versus 14% to 16% on placebo (Healio, December 20, 2024). That gives OSA patients a coverage route that does not depend on a weight-loss benefit.

What insurers have written down, as of September 5, 2026: Aetna's Zepbound policy (effective July 1, 2025) covers OSA with an apnea-hypopnea index of 15 or more on a polysomnogram or home sleep test, with a 6-month initial approval. Cigna's IP0206 (effective September 1, 2026) lists OSA among the comorbidities that qualify a patient with a BMI of 27 or higher. State Medicaid programs must cover Zepbound for OSA as an FDA-approved indication (KFF, January 2026), and Part D plans may. Ask your prescriber to submit the sleep study and the OSA diagnosis code, not just the BMI; the denial pattern we see is an OSA patient submitted under a weight-loss benefit the plan does not have.

If you are denied: what Zepbound costs in September 2026 without coverage

A denial is no longer a choice between a $1,000-plus list price and giving up. These are the cash routes as of September 4 and 5, 2026.

Route	Price	Conditions	Source
Zepbound savings card, commercially insured but not covered	$499 per one-month fill	Commercial insurance required; no Medicare or Medicaid; card expires December 31, 2026	zepbound.lilly.com, coverage and savings
Zepbound savings card, plan covers it	As little as $25 per fill	Maximum benefit $100, $200 or $300 per one-, two- or three-month fill; $1,300 per year; 13 fills	zepbound.lilly.com
LillyDirect self-pay vial or KwikPen	$299 (2.5 mg), $399 (5 mg), $449 (7.5 to 15 mg)	$449 tier requires a refill within 45 days of the last delivery; otherwise $499 (7.5 mg) or $699 (10 to 15 mg); no insurance involved	lilly.com/lillydirect/zepbound
Retail pharmacy with a GoodRx coupon	KwikPen $299	Listed at Walgreens, CVS, Walmart, Costco, Sam's Club and Target; cannot be combined with insurance	goodrx.com/zepbound, September 5, 2026
Zepbound single-dose pens at list price	About $1,086 per month	The insurance-billed product; rarely paid in full by anyone	WeightWatchers cost article, March 11, 2026
Medicare GLP-1 Bridge	$50 per month	Zepbound KwikPen; July 1, 2026 to December 31, 2027; prior authorization	healthinsurance.org
Compounded tirzepatide via telehealth	Median $299 for month 1 (range $149 to $470, n=14)	Not FDA-approved; no insurance; some providers add a membership fee; see the Compounded GLP-1 Price Index	FormBlends price index, September 3, 2026

For FormBlends compounded tirzepatide, the current price is on the product page and in our price index; we do not print it in articles because it changes.

FAQ

How long does it take to get Zepbound approved by insurance?

The median approval time is 7 to 14 business days for commercial insurance plans. Medicare Advantage plans take 10 to 21 days. Expedited reviews (when delay would harm your health) are decided within 72 hours. If your provider submits incomplete documentation, add another 10 to 14 days for resubmission.

What BMI do you need for insurance to cover Zepbound?

Most commercial plans require BMI of 30 or higher, or BMI of 27 or higher with at least one weight-related comorbidity (diabetes, hypertension, sleep apnea, dyslipidemia). Medicare Advantage plans rarely cover Zepbound for weight loss regardless of BMI, covering it only for type 2 diabetes.

Does insurance cover Zepbound for weight loss?

Fewer than half of commercial plans do. GoodRx's coverage tracker (reviewed July 10, 2026) found that 60% of commercially insured people had no Zepbound coverage as of July 2026, 37% had restricted coverage and 4% unrestricted; among those covered, 88% face prior authorization or other limits. Where it is covered, plans require BMI documentation and months in a lifestyle program (3 at Cigna, 6 at Aetna). Medicare covers Zepbound for sleep apnea, and for obesity only through the $50 GLP-1 Bridge from July 1, 2026.

Why did my insurance deny Zepbound?

The reasons that appear in insurer policies and denial letters are: no documented lifestyle-program trial of the required length (3 months at Cigna, 6 months at Aetna), a BMI below 30 (or below 27 with a listed comorbidity), incomplete step therapy, and a plan that excludes weight-loss drugs outright, which no appeal can overturn. No insurer publishes how often each reason occurs; an earlier version of this answer gave percentages that had no source. Check the denial letter for the stated reason and the 180-day appeal deadline.

Can I appeal a Zepbound insurance denial?

Yes. You have the right to an internal appeal (usually two levels) and then an independent external review. Under federal rules you must file the internal appeal within 180 days of the denial notice; the insurer must decide a prior-authorization appeal within 15 days (72 hours if urgent); and you have 4 months to request external review, which is decided within 45 days (healthcare.gov). Fewer than 1% of denials are ever appealed, and Claimable reports that about 40% of the denials it takes to external review are overturned (March 2026, company data).

Does Blue Cross Blue Shield cover Zepbound?

Coverage varies by state and specific plan. Most Blue Cross Blue Shield plans cover Zepbound with prior authorization for patients meeting BMI and comorbidity criteria. No Blue plan publishes first-attempt approval rates; an earlier version of this answer gave one and it has been removed. Check your specific plan's formulary for requirements.

Does UnitedHealthcare cover Zepbound?

UnitedHealthcare covers Zepbound for most commercial plans with prior authorization. Required criteria typically include BMI over 30 (or 27 with comorbidities), documentation of 12+ weeks of diet and exercise, and contraindication screening. UnitedHealthcare does not publish approval rates; its GLP-1 policy effective July 1, 2026 sets 12-month authorizations for diabetes agents and excludes weight-loss use under that policy, so Zepbound coverage depends on whether your employer bought a weight-loss benefit.

Does Medicare cover Zepbound for weight loss?

Partly, as of 2026. Part D has long covered Mounjaro for type 2 diabetes, and it can cover Zepbound for obstructive sleep apnea since the FDA approved that use on December 20, 2024. For obesity itself, the Medicare GLP-1 Bridge runs from July 1, 2026 to December 31, 2027: $50 a month for the Zepbound KwikPen, the Wegovy pen and pill, and Foundayo, with prior authorization, and it sits outside the $2,100 Part D out-of-pocket cap (healthinsurance.org).

How much does Zepbound cost with insurance?

With insurance approval, copays range from $25 to $500 per month depending on your formulary tier and whether you use the Lilly savings card. Patients with high-deductible plans pay full negotiated price ($900 to $1,100) until the deductible is met, then the lower copay applies.

What is step therapy for Zepbound?

Step therapy requires you to try less expensive medications first before the insurer will cover Zepbound. Common required steps include 90-day trials of phentermine, metformin, or orlistat. Approximately 16% of Zepbound denials cite incomplete step therapy. Your provider must document these trials with dates and outcomes.

Can my doctor write a letter to get Zepbound covered?

Yes. A letter of medical necessity from your provider can support your prior authorization, especially for borderline cases. Effective letters include your complete weight history, documented previous interventions, specific comorbidities with supporting labs, and peer-reviewed evidence. Letters should be 1 to 2 pages on provider letterhead.

Does the Lilly savings card work if insurance denies Zepbound?

Yes, at a fixed price. Under the 2026 terms (through December 31, 2026), commercially insured patients whose plan does not cover Zepbound pay $499 for a one-month fill. If your plan does cover it, the card brings the copay to as little as $25 per fill, capped at $100, $200 or $300 per one-, two- or three-month fill and $1,300 a year across 13 fills. It does not work for Medicare, Medicaid or patients with no insurance.

How long does it take to get approved for Zepbound?

There is no published average. A complete first submission that meets the plan's written criteria can come back within days; the federal outer limits apply to appeals, where the insurer must decide a prior-authorization appeal within 15 days (72 hours if urgent) and an external review within 45 days (healthcare.gov, seen September 5, 2026). Initial approvals then run 8 months at Aetna and Cigna and 12 months under UnitedHealthcare's GLP-1 policy.

Does Medi-Cal cover Zepbound in California?

Not for obesity. KFF's January 16, 2026 Medicaid brief reports that California was one of four states (with New Hampshire, Pennsylvania and South Carolina) that dropped Medicaid coverage of GLP-1s for obesity in 2026, leaving 13 state programs that still cover it. Medi-Cal must still cover the FDA-approved non-obesity uses: Mounjaro for type 2 diabetes and Zepbound for obstructive sleep apnea, subject to prior authorization.

Will insurance cover Zepbound for sleep apnea?

Often, and under different rules than weight loss. Zepbound has been FDA-approved for moderate-to-severe obstructive sleep apnea in adults with obesity since December 20, 2024. Aetna's policy (effective July 1, 2025) approves it for OSA with an apnea-hypopnea index of 15 or more, for 6 months initially; Cigna's IP0206 lists OSA as a qualifying comorbidity; Medicaid must cover the indication; Part D plans may. Submit the sleep study, not just the BMI.

How much is Zepbound with insurance in 2026?

If your commercial plan covers it, the Lilly savings card brings the copay to as little as $25 per fill, with the card paying at most $100, $200 or $300 per one-, two- or three-month fill and $1,300 a year, through December 31, 2026. If your commercial plan does not cover it, the card sets a flat $499 per month. Medicare beneficiaries in the GLP-1 Bridge pay $50 a month for the KwikPen from July 1, 2026 (healthinsurance.org).

Related guides

• How to Get Zepbound Covered by Insurance: The 2026 Playbook for Prior Authorization, Appeals, and Formulary Wins
• How to Get Insurance to Cover Zepbound in 2026: The Complete Prior Authorization Strategy
• How to Get Insurance to Cover Ozempic for Weight Loss in 2026: The Complete Prior Authorization Strategy
• How to Get Insurance to Cover Weight Loss Medication: The 2026 Prior Authorization Strategy That Actually Works
• How to Get Mounjaro Covered by Insurance Without Diabetes: The 2026 Prior Authorization Strategy That Actually Works
• How to Get a GLP-1 Covered by Insurance: The Prior Authorization Strategy That Actually Works
• Tool: cost calculator

Sources

1. Eli Lilly and Company. Zepbound prescribing information. Revised 2024.
2. American Medical Association. 2025 Prior authorization physician survey. AMA. 2025.
3. Kaiser Family Foundation. Employer health benefits survey 2025. KFF. 2025.
4. Centers for Medicare and Medicaid Services. Medicare Part D coverage determination and appeals guidance. CMS. 2024.
5. Jastreboff AM et al. Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine. 2022;387:205-216.
6. Garvey WT et al. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nature Medicine. 2022;28:2083-2091.
7. Rubino D et al. Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity: the STEP 4 randomized clinical trial. JAMA. 2021;325:1414-1425.
8. Wilding JPH et al. Once-weekly semaglutide in adults with overweight or obesity. New England Journal of Medicine. 2021;384:989-1002.
9. Wadden TA et al. Effect of subcutaneous semaglutide vs placebo as an adjunct to intensive behavioral therapy on body weight in adults with overweight or obesity: the STEP 3 randomized clinical trial. JAMA. 2021;325:1403-1413.
10. Davies M et al. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. Lancet. 2021;397:971-984.
11. Mercer. National survey of employer-sponsored health plans 2025. Mercer Health. 2025.
12. Cigna. Drug Coverage Policy IP0206, Weight Loss GLP-1 Agonists, effective September 1, 2026. https://static.cigna.com/assets/chcp/pdf/coveragePolicies/pharmacy/ip_0206_coveragepositioncriteria_weight_loss_glp1.pdf
13. Aetna. Pharmacy Clinical Policy Bulletin, Zepbound PA with Limit (6947-C), effective July 1, 2025. https://www.aetna.com/products/rxnonmedicare/data/2025/Zepbound_PA_with_Limit_FE_Compatible_6947-C_P04-2025.html
14. UnitedHealthcare. Prior authorization notification, Diabetes Agents, GLP-1 Receptor Agonists, effective July 1, 2026. https://www.uhcprovider.com/content/dam/provider/docs/public/prior-auth/drugs-pharmacy/commercial/a-g/PA-Notification-Diabetes-Agents-GLP1-Receptor-Agonists.pdf
15. CVS Health. CVS Caremark delivers affordability and access to GLP-1 weight management medications with expanded coverage options, May 28, 2026. https://www.cvshealth.com/news/company-news/cvs-caremark-delivers-affordability-and-access-to-glp-1-weight-management-medications-with-expanded-coverage-options.html
16. GoodRx Research. Live updates: tracking insurance coverage for GIP and GLP-1 agonists, reviewed July 10, 2026. https://www.goodrx.com/healthcare-access/research/tracking-insurance-coverage-weight-loss-meds
17. KFF. 2025 Employer Health Benefits Survey, October 22, 2025. https://www.kff.org/health-costs/2025-employer-health-benefits-survey/
18. KFF. Medicaid coverage of and spending on GLP-1s, January 16, 2026. https://www.kff.org/medicaid/medicaid-coverage-of-and-spending-on-glp-1s/
19. healthinsurance.org. Does health insurance cover drugs used for weight loss such as Ozempic, Wegovy, Mounjaro and Zepbound? Seen September 4, 2026. https://www.healthinsurance.org/faqs/does-health-insurance-cover-drugs-used-for-weight-loss-such-as-ozempic-wegovy-mounjaro-and-zepbound/
20. Healio. FDA approves Zepbound for moderate to severe OSA in adults with obesity, December 20, 2024. https://www.healio.com/news/pulmonology/20241220/fda-approves-zepbound-for-moderate-to-severe-osa-obesity
21. HealthCare.gov. Internal appeals and external review deadlines, seen September 5, 2026. https://www.healthcare.gov/appeal-insurance-company-decision/internal-appeals/ and https://www.healthcare.gov/appeal-insurance-company-decision/external-review/
22. Claimable. Insurance won't cover Zepbound? How to appeal, March 12, 2026 (company data). https://www.getclaimable.com/post/insurance-wont-cover-zepbound
23. Eli Lilly. Zepbound coverage and savings card terms, 2026 program year, seen September 4, 2026. https://zepbound.lilly.com/coverage-savings
24. Eli Lilly. LillyDirect Zepbound self-pay pricing, seen September 4, 2026. https://www.lilly.com/lillydirect/zepbound
25. GoodRx. Zepbound prices and coupons, seen September 5, 2026. https://www.goodrx.com/zepbound
26. WeightWatchers. How much does Zepbound cost? March 11, 2026 (list price $1,086.37). https://www.weightwatchers.com/us/blog/weight-loss/zepbound-cost
27. FormBlends. Compounded GLP-1 Price Index feed, as of September 3, 2026. https://formblends.com/feeds/glp1-prices.json

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Zepbound and Mounjaro are registered trademarks of Eli Lilly and Company. Ozempic and Wegovy are registered trademarks of Novo Nordisk A/S. UnitedHealthcare, Anthem, Blue Cross Blue Shield, Aetna, Cigna, Humana, and Kaiser Permanente are trademarks of their respective owners. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.